Prognosis analysis of different metastasis patterns

This interesting study reviewed the different metastasis patterns in patients with different breast cancer subtypes.

It's a long and complex read but the information is very revelatory.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC54322...

Abstract

Studies on prognosis of different metastasis patterns in patients with different breast cancer subtypes (BCS) are limited. Therefore, we identified 7862 breast cancer patients with distant metastasis from 2010 to 2013 using Surveillance, Epidemiology, wand End Results (SEER) population-based data. The results showed that bone was the most common metastatic site and brain was the least common metastatic site, and the patients with HR+/HER2− occupied the highest metastasis proportion, the lowest metastasis proportion were found in HR-/HER2+ patients. Univariate and multivariate logistic regression analysis were used to analyze the association, and it was found that there were significant differences of distant metastasis patterns in patients with different BCS(different P value). Importantly, univariate and multivariate Cox regression analysis were used to analyze the prognosis. It was proven that only bone metastasis was not a prognostic factor in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subgroup (all, P > 0.05), and patients with brain metastasis had the worst cancer specific survival (CSS) in all the subgroups of BCS (all, P<0.01). Interestingly, for patients with two metastatic sites, those with bone and lung metastasis had best CSS in the HR+/HER2- (P<0.001) and HR+/HER2+ subgroups (P=0.009) However, for patients with three and four metastatic sites, there was no statistical difference in their CSS (all, P>0.05).

Thanks for sharing.

Sjacobs, these are total numbers. HR+ HER2- represent the greatest number of breast cancer cases, by far, so it skews the numbers. Triple negative is very aggressive, but since it represents a smaller percentage of cases, the numbers seem low, where as, they likely represent more in proportion of women diagnosed. Unfortunately, those numbers are not accurately tracked anywhere.